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ABSTRACT 
Advanced glycation end products (AGEs) are implicated in the pathology of Alzheimer’s disease (AD), 
as they induce neurodegeneration following interaction with the receptor for AGE (RAGE). This study 
aimed to establish a mechanistic link between AGE-RAGE signaling and AD pathology. AGE-induced 
changes in the neuro2a proteome were monitored by SWATH-MS. Western blotting and cell-based 
reporter assays were used to investigate AGE-RAGE regulated APP processing and tau phosphorylation 
in primary cortical neurons.  Selected protein expression was validated in brain samples affected by AD. 
AGE-RAGE axis altered proteome included increased expression of Cathepsin B and asparagine 
endopeptidase (AEP), which mediated increase in Aβ1-42 formation and tau phosphorylation, respectively.  
Elevated Cathepsin B, AEP, RAGE, and pTau levels were found in human AD brain coincident with 
enhanced AGEs. This study demonstrates that AGE-RAGE axis regulates Aβ1-42 formation and tau 
phosphorylation via increased Cathepsin B and AEP, providing a new molecular link between AGEs and 
AD pathology. 
KEYWORDS: Advanced glycation end products, Alzheimer’s disease, Amyloid beta, Asparagine 
endopeptidase, Cathepsin B, Diabetes, Proteomics, Tau phosphorylation. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a one of the major causes of dementia in older people leading to cognitive 
dysfunction.1 AD is characterized by accumulation of insoluble extracellular senile plaques and 
intracellular neurofibrillary tangles.2, 3 The disease affects over 47 million people worldwide and this 
number is expected to increase to more than 131 million by 2050 as per the World Alzheimer Report 
2016. AD is a multifactorial syndrome involving several molecular and cellular processes including 
inflammation, mitochondrial dysfunction, glycation, protein aggregation, oxidative stress and 
hyperglycemia.4-8  
The occurrence of AD is significantly higher in an aging population, as well as in subjects with diabetes, 
suggesting that dysregulation in glucose metabolism could be one of the causal factors.9, 10 The peptide 
hormone insulin has been directly implicated in tau hyperphosphorylation via activation of ERK and 
GSK3β. Thus hyperinsulinemia is associated with neurofibrillary tangles formation and hence AD 
progression. In contrast, insulin is also known to promote processing of APP through a non-
amyloidogenic pathway, and insulin resistance is associated with increased deposition of Aβ and reduced 
brain function.10-13 The inevitable consequence of increased insulin resistance is hyperglycemia leading to 
protein glycation. Glycation is a non-enzymatic reaction between glucose or other glycolysis 
intermediates and proteins leading to formation of heterogeneous advanced glycation end products 
(AGEs).14 The levels of AGEs increase during biological aging due to decreased efficiency of 
homeostatic processes.15 AGEs are associated with AD pathology and are likely involved in the formation 
of amyloid plaques and neurofibrillary tangles.7, 16-18 AGEs can induce toxic effects through interactions 
with the cell surface AGE receptor (RAGE). AD brain shows increased RAGE expression which is 
involved in the intraneuronal transport of Aβ peptides leading to mitochondrial damage and neuronal 
dysfunction.19, 20 Furthermore, glycated Aβ has been shown to exacerbate neuronal damage, through 
interaction with RAGE, as it acts as a more suitable ligand over unmodified Aβ.21 Blocking RAGE 
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signaling with the inhibitor, FPS-ZM1, was found to be effective in reducing Aβ-mediated neuronal 
dysfunction in an AD mouse model highlighting the potential importance of AGE-RAGE in AD 
pathology and progression.22 The precise mechanisms involved are not fully defined but RAGE 
stimulation leads to activation of NADPH oxidases which induces reactive oxygen species (ROS) 
generation. Redox imbalance induces activation of several signal transduction pathways which damage 
cells and tissues severely.23  
Thus, the aim of the current study was to explore the change in the neuronal protein profile in response to 
AGE-RAGE signaling and investigate the role of selected regulated proteins in the development of AD 
pathology. Human serum albumin (HSA) is the predominant AGE modified protein in plasma, and AD 
individuals show increased glycated proteins in Cerebrospinal fluid.24, 25  Using AGE-HSA as a ligand for 
RAGE, we performed label-free quantitative proteomic analysis by SWATH-MS, showing that 
AGE/RAGE axis regulates several key proteins implicated in AD including Cathepsin B, asparagines 
endopeptidase (AEP), acid ceramidase and CD147. The AGE/RAGE axis stimulated an increase in 
Cathepsin B-mediated APP processing, which was associated with increased Aβ1-42 formation in primary 
cortical neurons. AGE/RAGE interaction also led to increased tau phosphorylation. Further, we have 
observed increased levels of RAGE, Cathepsin B and AEP correlating with higher levels of AGE 
modified proteins and phosphorylated tau in brain homogenates from the temporal cortex of individuals 
affected by AD. Hence this study describes a direct association between the AGE/RAGE axis and the 
development of AD providing a new mechanistic link between AGEs and dementia. 
RESULTS  
Synthesis of AGE-HSA 
AGE-HSA was synthesized by co-incubating glucose and HSA for 90 days under sterile conditions. 
Formation of AGEs was confirmed by measuring AGE-specific fluorescence and western blotting with 
anti-carboxymethyllysine (CML) antibody as showed in Figure S2 (Supplementary). Furthermore, AGE-
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HSA was thoroughly characterised for AGE modifications using high resolution accurate mass 
spectrometry (Supplementary methods). A list of modified peptides is provided in Supplemental Table 
S1.  
AGE-HSA induces ROS and apoptosis in neuro2a cells  
AGE-RAGE axis activates NADPH oxidase and stimulates reactive oxygen species (ROS) production26, 
which further activates NF-κB leading to inflammation and apoptosis.27 Therefore, to investigate the role 
of AGE-RAGE axis, we have studied the effects of AGE-HSA on cell viability, ROS production and 
apoptosis. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) dye reduction assay, an indicator of metabolic status. AGE-HSA was significantly cytotoxic to 
neuro2a cells at a concentration of 1.5 mg/ml and above (Figure 1) compared to unmodified HSA, which 
was used as a control. Lower concentration of AGE-HSA (0.1, 0.5 and 1 mg/ml) however, did not show 
any cytotoxic effects (Figure 1). Therefore, AGE-HSA at a non-cytotoxic concentration of 1 mg/ml was 
chosen to conduct all subsequent experiments. Next, the influence of AGE-HSA on ROS production was 
studied by 2′,7′-Dichlorofluorescin diacetate (DCF-DA) staining. ROS induced formation of fluorescent 
2′, 7′-dichlorofluorescein was monitored by fluorescent spectrometry. HSA and AGE-HSA stimulation 
showed 1.08 and 1.35 fold increase in the levels of ROS respectively as compared to control (Figure 2A). 
Images acquired using fluorescence microscope also showed increase in the DCF-DA fluorescence in 
AGE-HSA stimulated cells (Figure 2B).  Furthermore, AGE-HSA induced apoptosis was studied using 
Annexin V-FITC staining followed by flow cytometry. Cells treated with AGE-HSA showed 7 % 
apoptotic cells, which is about 2 fold higher than unmodified HSA (Figure 2 C-E).  
AGE-HSA regulates expression of key proteins involved in AD     
Proteomic analysis (SWATH-MS) was performed to better understand the effect of AGE-HSA on 
neuronal cells. A spectral library created from tryptic peptides of control and AGE-HSA treated cells 
comprised of 1610 proteins (Supplemental Table S2). SWATH analysis revealed expression of 35 up 
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regulated (>2 fold) and 36 down regulated (<2 fold) proteins upon AGE-HSA induction compared to 
HSA (Supplemental Table S3). Functional annotation by DAVID analysis suggested that the 
differentially expressed proteins were involved in diverse biological processes as shown in Figure 3A and 
3B. Briefly, up regulated proteins were involved in fatty acid metabolism, proteolysis, lipid metabolism 
and redox processes (Supplemental Table S4), while down regulated proteins were involved in mRNA 
processing, protein synthesis and transport and cell adhesion. Furthermore, the differentially expressed 
proteins were subjected to iRegulon analysis, a cytoscape plugin for prediction of transcription factors 
which probably regulate these proteins. It showed that the up regulated proteins might be co-regulated by 
transcription factors such as Nfyb, Hsf2 and Gfi1b (Figure 3C), while down regulated proteins might be 
co-regulated by transcription factors such as Etv4 and E2f1 (Figure 3D). Protein-protein interaction 
network analysis revealed interactions of differentially regulated proteins and were found to be involved 
mainly in the lysosomal degradation pathway (Figure 3E). The most notable findings from the proteomic 
analysis was the up regulation of number of lysosomal proteins; Cathepsin B (4.83, p=0.04), asparagine 
endopeptidase (AEP)/legumain (4.71, p=0.00003) and acid ceramidase (5.40, p=0.003) and the down 
regulation of CD147 (0.46, p=0.02), as these proteins have been directly implicated in AD (Figure 3F). 
AGE-HSA regulates the expression of Cathepsin B and AEP in mouse primary cultured cortical 
neurons through RAGE 
Exposure to AGEs caused 184.51% and 546.87% increase in the expression of Cathepsin B and AEP 
respectively in neuro2a cells confirming the initial proteomic analysis (Figure 4A, 4B and 4C). As 
Cathepsin B and AEP are directly involved in Aβ formation and tau hyperphosphorylation respectively28, 
29, we also studied the AGE-RAGE-dependent expression of these two proteins in primary cortical 
neurons, which is a better model system for investigating the regulation of these proteins. The expression 
of RAGE was confirmed in primary cortical neurons by western blotting (Figure S3, supplementary) and 
AGE-HSA was not toxic at 1.0 mg/ml as shown by MTT assay (Figure S4, supplementary). Expression of 
Cathepsin B and AEP following exposure to AGEs was studied by Western blotting. As predicted, 
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Cathepsin B and AEP expression was elevated by 154.78% and 208.64% respectively in response to 
AGEs. Significantly, blocking RAGE with an anti-RAGE antibody (H300) abolished AGE-induced 
Cathepsin B and AEP expression demonstrating that up regulation requires an AGE-RAGE interaction 
(Figure 4D, 4E and 4F).  
AGE-RAGE interaction increases Cathepsin B-dependent APP processing, β-CTF formation and 
Aβ generation   
Cathepsin B is a well-characterized lysosomal cysteine protease in mammalian cells which plays an 
important role in intracellular proteolysis.30 It selectively cleaves APP at the Beta-secretase 1 (BACE1) 
site31 and is associated with the accumulation of Aβ1-40 and Aβ1-42. Furthermore, the Cathepsin B inhibitor, 
CA074Me, reduces brain Aβ deposition and improves memory deficits in AD animal models by 
inhibiting Cathepsin B.31 Transgenic mice lacking the Cathepsin B gene displayed reduced Aβ 
deposition.32, 33 All these studies suggest an important role for Cathepsin B in APP processing and AD 
pathology. AGEs increase BACE1 expression 34 but effects on Cathepsin B are much less clear. Hence, 
we studied the sensitivity of APP processing to a selective Cathepsin B inhibitor, CA074Me using an 
APP-GAL4 luciferase reporter assay in primary cortical neurons which preferentially reports 
amyloidogenic βγ-secretase dependent processing. 35, 36 Exposure to AGE-HSA, but not HSA alone, led to 
a robust increase in luciferase expression that was sensitive to the γ-secretase inhibitor N-[N-(3,5-
Diflurophenaacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester (DAPT)suggesting that AGEs couple to an 
amyloidogenic APP processing pathway in neurons (Figure 5A). Notably the AGEs-induced increase in 
luciferase expression was reversed in the presence of Cathepsin B inhibitor CA074Me suggesting that 
AGE-HSA induced increases in APP processing was mediated primarily by Cathepsin B (Figure 5B). 
Furthermore, the anti-RAGE antibody H300 also strongly inhibited APP processing, indicating that AGEs 
increase APP processing via association with RAGE (Figure 5B). Cathepsin B gene knockout mice have 
substantially reduced levels of the C-terminal β-secretase fragment (β-CTF) derived from APP 
processing,32 hence APP-CTFs were measured after exposure of neurons to AGE-HSA (Figure 5C). 
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AGE-HSA treatment appeared to increase β-CTF formation compared with control or HSA alone, as seen 
as a diffuse band around 10 kDa by Tris-tricine SDS-PAGE followed by Western blot with anti-APP-CTF 
antibody. Treatment with the Cathepsin B inhibitor CA074Me or the anti-RAGE antibody H300, 
decreased β-CTF formation suggesting that Cathepsin B regulated β-CTF formation is downstream of 
activation of the AGE-RAGE axis. Elevated β-CTF levels in neurons could equally be mediated by β-
secretase; therefore, the effect of the BACE1 inhibitor, AZD3293 on AGEs-mediated β-CTF formation 
was also investigated. AZD3293 also reduced β-CTF formation and appeared to switch processing to the 
formation of α-CTFs as seen as a diffuse lower molecular weight band. Collectively, these findings 
suggest that both Cathepsin B and β-secretase contribute to AGE-mediated β-CTF formation. 
Furthermore, in order to determine if activation of the AGE-RAGE axis resulted in Aβ formation we also 
quantified Aβ1-42 levels by ELISA in the growth media of AGE-HSA treated primary cortical neurons. 
Exposure of primary cortical neurons to AGE-HSA resulted in a ~two-fold increase in the secretion of 
Aβ1-42 compared with HSA alone and a ~3-fold increase in Aβ1-42 compared with non-treated control 
(Figure 5D). The AGEs-induced increase in Aβ1-42was reduced by treatment with either CA074Me or 
H300 consistent with our hypothesis that AGEs couple to amyloidogenic APP processing through 
recruitment of the AGE-RAGE axis and subsequent activation of Cathepsin B.  AZD3293 also reduced 
AGE-induced Aβ1-42 secretion but this was likely due to a strong inhibitory effect on basal Aβ1-42 levels in 
the absence of AGEs which is in general agreement with previous reports that the favoured constitutive 
APP processing route in primary neurons is via BACE.  
AGE-HSA induces tau phosphorylation 
Our initial proteome measurements demonstrated that AGEs up regulate the expression of AEP in 
neurons.  Previous studies have implicated AEP in hyperphosphorylation of tau via activation of inhibitor 
of protein phosphatase 2A (PP2A) involved in dephosphorylation of tau28, 37 and the AGE-RAGE axis 
activates various kinases including Akt, ERKs, GSK3β,38 which are also involved in 
hyperphosphorylation of tau. Therefore, we assessed the tau phosphorylation status in response to AGE-
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HSA treatment in primary cortical neurons. Neither HSA nor AGE-HSA altered the levels of tau (Figure 
6), but enhanced tau phosphorylation, as evidenced by elevated phosphorylation at Serine396 after AGE-
HSA stimulation. However, the increase in pTau S396 observed with AGE-HSA was not restored 
following co-incubation with an anti-RAGE antibody (H300) (Figure 6) suggesting a mechanism of 
regulation independent of RAGE 
Validation of AGE, RAGE, Cathepsin B, AEP and phosphorylation of tau in the AD brain  
CML, a predominant AGE modification39 was analyzed in human tissue homogenates prepared from the 
temporal cortex of AD and control brains.  A representative western blot of 6 subjects, 3 each of healthy 
age matched control and AD patients are showed in Figure 7A. Quantification of western blot revealed 
that there was 1.35 fold increase (p=0.1486) in CML modification of proteins in the brain lysate of AD 
patients as compared to healthy subjects (Figure 7B). Further accumulation of AGEs is associated with 
elevated RAGE expression.40 As expected, AD brain showed 1.31 fold (p=0.1290) increase in levels of 
RAGE expression as compared to age matched controls (Figure 7C).  Cathepsin B and AEP expression 
were also markedly increased by 1.82 (p=0.0957) and 1.56 (p=0.0268) fold respectively in the human AD 
brain (Figure 7D and 7E) supporting the proteome and functional data obtained in cell models. The 
elevated expression of AEP was also reflected with increased tau phosphorylation (2.51 fold, p=0.1202) 
in AD subjects. Further, levels of RAGE, Cathepsin B, AEP, pTau and CML modified proteins in Normal 
and AD subjects was normalized with beta-tubulin which revealed significant increase in their levels 
across the groups (Table 1). To our knowledge, this is the first study that reports increased expression of 
Cathepsin B and AEP in AD brain. 
Discussion 
The RAGE is a multi-ligand transmembrane receptor which interacts with various ligands including 
advanced glycation end products (AGEs), HMGB, S100, and Aβ. Long-lived proteins are preferentially 
glycated to form AGEs, which interact with RAGE and exacerbate neurodegeneration.41 The proteasomal 
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system is impaired during aging leading to accumulation of modified proteins including AGEs.  
Furthermore, protein glycation is increased in the Cerebrospinal fluid of individuals with AD as compared 
with age-matched controls.24, 42, 43 Glycated Aβ is hypothesized as a more suitable ligand for RAGE21 and 
high levels of AGEs are associated with poorer learning in AD mice.44 Several studies show RAGE 
dependent increase in ROS generation which further activates nuclear factor (NF)-κB.27 NF-κB plays an 
important role in transducing inflammatory and pro-apoptotic signals.45 RAGE-dependent activation of 
NF-κB leads to the up-regulation of RAGE itself.46 Noticeable increase in RAGE levels and oxidative 
damage is observed in the brain of AD subjects suggesting vital role of ROS in the development AD.8, 47 
Despite decades of evidences that shows AGEs accumulate during AD, influence Aβ toxicity and 
clearance, and drive changes through redox actions,48, 49 the precise molecular mechanisms linking AGEs 
to the development and progression of AD pathology are still not well understood. In this study we have 
investigated the change in proteome in response to AGE treatment in neuro2a cells using label free 
quantitative approach (SWATH-MS) to discover new proteins and pathways that lead to AD progression 
downstream of the AGE-RAGE axis. A number of key lysosomal proteins previously implicated in AD, 
including Cathepsin B, asparagine endopeptidase (AEP) and acid ceramidase, were up regulated by 
AGEs.  Activation of the AGE-RAGE axis in neurons stimulated Cathepsin B-mediated APP processing 
and increased Aβ1-42 formation.  Furthermore, AGE-RAGE signaling increased expression of AEP and tau 
phosphorylation. 
Cathepsin B, a cysteine protease, is involved in APP processing through its BACE1 activity leading to 
elevated Aβ formation. Inhibitors of Cathepsin B, CA074Me and E64d, have been shown to improve 
memory function by reducing Aβ levels in transgenic mice overexpressing wild type APP.29, 31 The 
improvement in memory was also demonstrated by Cathepsin B gene knock out in transgenic mice 
overexpressing wild type APP.32, 33 In our study also we have demonstrated AGE-HSA induced 
upregulation of Cathepsin B in neuro2a, primary cortical neurons, and in brain tissue from individuals 
with AD subjects. Interestingly, higher levels of Cathepsin B have previously been reported in the plasma 
of AD subjects.50 The increased expression of Cathepsin B was also associated with enhanced 
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amyloidogenic APP processing, β-CTF and Aβ1-42 formation all of which were reduced in the presence of 
a Cathepsin B inhibitor or by H300 an anti-RAGE antibody. Collectively, this study suggests that 
Cathepsin B may have a potential role in aggravating the onset and development of Aβ1-42 pathology in 
sporadic AD particularly in association with type II diabetes where elevated levels of AGEs may induce 
up regulation of Cathepsin B expression.   
Neurofibrillary tangles, the second major pathological hallmark of AD are characterized by tau 
hyperphosphorylation. The deregulation of protein kinases and/or protein phosphatases is probably the 
primary cause of elevated tau phosphorylation.51 Several protein kinases including members of the 
MAPK family, GSK-3β, cyclin-dependent kinase 5 (cdk5), can phosphorylate tau and are regulated by 
AGE/RAGE axis.52-54 Methylglyoxal induced AGEs are linked with tau hyperphosphorylation through 
GSK-3β and p38 MAPK activation.55 Protein phosphatase 2A (PP2A) is predominantly associated with 
the dephosphorylation of tau. In vivo PP2A activity is regulated by a protein called inhibitor-2 (I2
PP2A).  
The I2
PP2A is cleaved by asparagine endopeptidase (AEP) into active fragments, N-terminal (I2NTF) and C-
terminal (I2CTF), which binds to  PP2A leading to its inactivation.
37 Hence, elevated expression of AEP is 
associated with decreased PP2A activity leading to tau hyperphosphorylation highlighting its potential 
role in AD pathology.28 In this study, we demonstrated AGE-HSA induced up regulation of AEP in 
neuro2a and primary cortical neurons. AEP levels were found to be elevated in brain tissue of AD 
subjects. The increased expression of AEP was also associated with increased tau phosphorylation which 
was notrestored by pre-treatment with anti-RAGE antibody suggesting a RAGE independent regulation.  
AEP plays a critical role in tau-related clinical and neuropathological changes during aging which 
degrades tau, terminate its microtubule assembly function, induces tau aggregation and triggers 
neurodegeneration. Hence, inhibition of AEP is a potential therapeutic approach to treat tau-mediated 
neurodegenerative diseases.56 
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CONCLUSION  
In summary, using label free quantitative proteomics approach (SWATH-MS), a total of 1196 proteins 
were identified from murine neuro2a cells after HSA and AGE-HSA stimulation. AGE induced 
differential expression of 71 proteins, of which 35 were up regulated and 36 down regulated. 
Differentially regulated proteins included Cathepsin B, AEP, acid ceramidase and CD147, all of which 
have been implicated in AD pathology. Furthermore, AGE-RAGE induced Cathepsin B mediated 
increase in Aβ1-42 formation was observed highlighting the importance of AGE/RAGE axis in APP 
processing. In addition to actions on Aβ pathology, an AGE-RAGE induced increase in tau 
phosphorylation was also established, perhaps via increased expression and activity of AEP. Individuals 
affected by AD showed notable increase in the expression of Cathepsin B and AEP signifying their 
potential deregulation in AD. This study for the first time demonstrates that AGEs regulate both Aβ1-42 
generation and tau phosphorylation, the two key hallmarks of AD, following increased expression of 
lysosomal proteases, thus providing a direct molecular link between the accumulation of AGEs and the 
development of AD pathology in sporadic disease and particularly in association with diabetes and 
hyperglycemia. 
METHODS 
Antibodies 
Cathepsin B was detected using rabbit anti-cathespin B antibody (Santa Cruz Biotechnology (SCBT), 
#sc-6493-R). Asparagine endopeptidase (AEP) was detected using rabbit anti-AEP antibody (Abcam, 
#ab125286). RAGE was detected by using rabbit anti-RAGE antibody (SCBT, #H-300). APP and APP-
CTFs were detected using monoclonal rabbit anti-APP C-terminal antibody (Abcam, #ab32136). Tau was 
detected using mouse monoclonal anti-tau46 antibody (Cell Signaling Technology (CST), #4019). Tau 
phosphosite-specific westerns were performed using the mouse monoclonal anti-pS396/PHF13 (CST, 
#9632) and anti-pSer202, pThr205/AT8 (Thermo scientific, #MN1020) antibodies. Carboxymethylation 
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of proteins was detected using rabbit anti-CML (Abcam, #ab27684) antibody. Anti-Tubulin Antibody, 
beta III isoform (Millipore, #MAB1637) was used as a routine loading control. Anti-mouse (Millipore, 
AP124P) and anti-rabbit (Millipore, AP132P) peroxidase conjugated secondary antibodies were used to 
detect primary antibodies.  
Cell culture  
Neuro2a cells were purchased from National Centre for Cell Science, Pune, India. Cells were cultured in 
DMEM (Himedia, #AL183A) supplemented with10% heat-inactivated fetal bovine serum (Himedia, 
#RM9955) at 37°C in 5% CO2.
57  The presence of RAGE in neuro2a cells was confirmed by Western 
blotting (Figure S1, Supplementary). Primary cortical neurons were prepared from CD1 mouse embryos 
in accordance with UK Home Office Guidelines as stated in the Animals (Scientific Procedures) Act 1986 
using Schedule 1 procedures approved by the University of Bath Animal Welfare and Ethical Review 
Body. Primary neurons were prepared essentially as described previously.58  Cortices were dissected from 
15-day-old CD1 mouse embryos, and were mechanically dissociated in PBS (Ca2+ and Mg2+ free) 
supplemented with 6mM glucose, using a serum coated fire-polished glass Pasteur pipette.  Cells were 
plated into either 12- or 24-well Nunc tissue culture plates, previously coated with 20 µg/ml poly-D-
lysine (Sigma). Neurons were cultured in neurobasal medium (Life Technologies, #12348017), 
supplemented with 2 mM glutamine, 100 µg/ml penicillin, 60 µg/ml streptomycin and B27 (Life 
Technologies, #10889038) and incubated at 37°C, in high humidity with 5% CO2. Under these growth 
conditions at 5-10 days in vitro (DIV) cells had a well-developed neuritic network and were 99% β-
tubulin III positive and <1% GFAP positive. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye reduction assay for cell 
viability 
The effect of AGEs on cell viability was determined by MTT assay. Neuro2a cells or primary cortical 
neurons were incubated with various concentrations of HSA or AGE-HSA (0.1, 0.5, 1, 1.5 mg/ml) for 24 
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h and MTT (2.4 mM) (Sigma, #M5655) was then added for a further3 h at 37°C in a 5% CO2 incubator. 
After incubation, the culture media was removed by aspiration and formazan crystals were dissolved in 
100% DMSO. The absorbance was measured at 550 nm using Bio-Rad iMark microplate reader.59  
Measurement of intracellular ROS 
ROS was detected by 2′, 7′-dichlorofluorescin diacetate (Sigma, #D6883) staining followed by plate-
based measurement of fluorescence and imaging. As the process of NADPH oxidase activation and ROS 
generation is an instantaneous process via adaptor molecules, ROS measurement was performed after 1h 
of AGE treatment. Cells were treated with HSA or AGE-HSA for 1 h at 37°C. After wash with PBS, the 
cells were stained with DCF-DA (10 µM) for 10 min at 37°C and fluorescence intensity was read using a 
fluorescence microplate reader (Thermo Scientific Varioskan Flash) at 485/528 nm excitation/emission 
wavelengths respectively.60, 61 Further, fluorescent images were captured by microscopy (Life 
technologies, Evos).  
Apoptosis assay  
AGE induced apoptosis was studied using an Annexin V-FITC apoptosis detection kit (Sigma, 
#APOAF).62, 63 Cells were treated with HSA or AGE-HSA for 24 h and stained with propidium iodide 
(PI) and Annexin V-FITC for 10 min.  Carboplatin (10 µM) or methylglyoxal (3 mM) was applied to cells 
to induce either apoptosis or necrosis respectively, followed by PI or Annexin V-FITC Staining. PI and 
FITC fluorescence was measured using an Accuri Flow Cytometer (BD Biosciences) as per the 
manufacturer’s instructions. Data analysis was performed using BD Accuri C6 software and the 
percentage of apoptotic cells was determined. 
Sample preparation for Mass spectrometric analysis 
Neuro2a cells were treated with HSA or AGE-HSA (1 mg/ml) for 24 h. Protein extraction was performed 
in 50 mM ammonium bicarbonate buffer containing 0.1% Rapigest SF (Waters, #186001860) followed 
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by 30 min incubation on ice with intermittent mixing. Protein concentration was determined using a Bio-
Rad Bradford assay kit. 100 µg of protein was used for digestion. Proteins were denatured by heating at 
80°C for 15 min. Further, proteins were reduced and alkylated by 100 mM dithiothreitol at 60°C for 15 
min and 200 mM iodoacetamide at room temperature for 30 min respectively. 4 µg of proteomics grade 
porcine trypsin (Sigma, # T6567) was added and incubated for 18 h at 37°C. Samples were acidified with 
formic acid to stop the digestion; tryptic peptides were desalted by using C18 zip-tips (Millipore, 
#ZTC18S096) and concentrated using vacuum concentrator.64 Peptides were reconstituted in 3% ACN 
with 0.1% formic acid before being subjected to LC-MS/MS analysis. 
Liquid chromatography-mass spectrometry analysis (SWATH-MS) 
All samples were analyzed on an AB Sciex Triple-TOF 5600 mass spectrometer coupled with micro LC 
200 (Eksigent) in high-sensitivity mode. To generate the SWATH spectral library, peptide digests of each 
treatment were analyzed by LC-MS/MS in an Information Dependent Acquisition (IDA) mode. All raw 
mass spectrometry data files have been deposited to the PeptideAtlas with the data set identifier 
PASS01086. A spectral library was created by combining the files of all the treatments. Accumulation 
time for MS and MS/MS was set to 0.25 ms and 0.01 ms respectively and fragmentation was undertaken 
using rolling collision energy. MS scans were performed in the mass range of 350-1800 m/z, with a 
charge state 2 to 5 and MS/MS was triggered for ions exceeding 120 cps.65  
SWATH-MS datasets were acquired (in biological duplicates and technical triplicates) on micro LC-
Triple TOF 5600.The desalted tryptic peptides were injected onto a Eksigent C18-RP HPLC column (100 
× 0.3 mm, 3 µm, 120 Å) at the flow rate of 8 µL/min over 120 min gradient conditions, solvent A (water 
with 0.1 % formic acid) and solvent B (ACN with 0.1 % formic acid): held at 97 % A for 5 min, 97-90 % 
A over 20 min, 90-70 % A over 70 min, 70-50 % A over 5 min, 50-10 % A over 1 min, at 10 % A for 7 
min, 10-97% A over 1 min and held at 97 % A for 11 min. For SWATH-MS data acquisition, the 
instrument was tuned to optimize the quadrupole settings for the precursor ion selection window of 25 Da 
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wide using 34 windows of 25 Da effective isolation width (with an additional 1 Da overlap) and with a 
dwell time of 70 ms to cover the mass range of 350-1200 m/z in 3.4 s. Before each cycle, an MS1 scan 
was acquired, and then the MS2 scan cycle started (350–375 m/z precursor isolation window for the first 
scan, 374–400 m/z for the second scan 1174–1200 m/z for the last scan). The collision energy for each 
window was set using the collision energy of a 2+ ion centered in the middle of the window with a spread 
of 15 eV.66  
Protein Identification and Quantification 
To obtain spectral library from IDA runs, data was analyzed by Protein Pilot software 5.0 (1% FDR) 
using UniProt Mus musculus database containing more than 16500 reviewed protein entries (2015). 
Validation was performed through a false discovery rate set to 1% at protein. Specificity of trypsin 
digestion was set for cleavage after lysine or arginine. The precursor and fragment initial mass error 
tolerance was set to 0.05 Da and 0.1 Da respectively. Spectral library was used as database for the 
analysis of SWATH data with MS and MS/MS mass error of 20 ppm and 30 ppm respectively. SWATH 
files were exported to Marker View which gives quantitative analysis of proteins, peptides and ions in 
different samples.65 
Experimental Design and Statistical Rationale 
The data set contains mass spectrometry results from the analysis of 2 biological and 3 technical 
replicates of neuro2a cell samples leading to 12 raw files considered for statistical analysis. For each 
analyzed sample, the values of the technical replicates were averaged and subjected to the statistical 
analysis. The proteins with a minimum 2-fold change (normalized with total intensity) and p values under 
0.05 were considered significantly regulated.  
DAVID and Cytoscape analysis 
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Mus musculus uniprot accessions of differentially expressed proteins were uploaded to functional 
annotation tool DAVID and functional clustering and pathway enrichment was performed with high 
stringency.67 Further, differentially regulated proteins were analysed using the iRegulon plugin of 
Cytoscape 3.3 to determine proteins under common regulator.68 The dysregulated proteins were further 
analysed for protein-protein interactions using String and closely interacting proteins were identified 
using MCL algorithm of Clustermaker2 plugin in Cytoscape.69 
Western blotting    
Neuro2a cells or primary cortical neurons were harvested in RIPA buffer (150 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 0.5% deoxycholic acid, 50 mM Tris–HCl, pH 7.5), kept on ice with intermittent mixing 
and centrifuged at 4°C. 10 µg of protein lysate was separated on 10% SDS-PAGE, transferred onto 
polyvinylidene difluoride (Millipore, #ISEQ10100) membrane and incubated for 1 h at room temperature 
in blocking buffer containing 3% BSA dissolved in PBST (NaCl 136.89 mM, KCl 2.68 mM, Na2HPO4 
10.14 mM and 0.1% Tween 20). The membranes were incubated overnight at 4°C with primary antibody 
in blocking buffer. The following antibodies were used, anti-Cathepsin B (1:500), anti-AEP (1:1000), 
anti-RAGE (1:500), anti-tau (1:1000), Anti-pS396Tau (1:1000), AT8 (1:1000) and anti-CML (1:2000). 
The membranes were incubated either with anti-rabbit or anti-mouse HRP conjugated secondary antibody 
at a dilution of 1:2500 for 60 min at room temperature. Immunodetection was performed using the 
Amersham ECL prime (GE Healthcare, RPN2232) western blotting detection reagent following the 
manufacturer's instructions.  
Detection of APP695 and APP C-terminal fragments  
Primary cortical neurons cultured in 6-well plates for 7-10 DIV were treated with either HSA or AGE-
HSA, in the presence or absence of anti-RAGE antibody (H300), Cathepsin B inhibitor (Calbiochem, 
#205531) and BACE 1 inhibitor (AZD3293) washed twice with cold PBS, and lysed in RIPA buffer, 
centrifuged, and protein was quantified. Proteins were resolved by 10% Tris-glycine SDS-PAGE for 
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APP695 and by 16.5% Tris-tricine SDS-PAGE for APP C-terminal fragments (CTFs).36 Following SDS-
PAGE, proteins were transferred onto 0.2 µm PVDF membrane. Western blotting for APP695 and APP 
CTFs (raised against 20 C-terminal amino acids of APP695) was performed using Y188 antibody 
(1:2000). Western blotting for beta tubulin was performed using beta tubulin primary monoclonal 
antibody (1:5000) and HRP-conjugated goat anti-mouse IgG secondary antibody (1:2500). APP695, APP-
CTFs and beta tubulin were detected using ECL prime advance system, as per the manufacturer’s 
instructions. 
Plasmids  
Three plasmids were used to assess the APP processing by the luciferase reporter assay. Full length APP 
cloned in pRC-CMV-APP695-Gal4 was used as described earlier.36 Briefly, it is a pRC-CMV vector 
encoding a human APP695 fused in-frame at its C-terminus to the yeast transcription factor Gal4 via a 
glycine hinge. pFR-Luciferase reporter vector with firefly (Photinus pyralis) luciferase gene under the 
control of a synthetic promoter containing 5 tandem repeats of the yeast Gal4 activation sequence 
upstream of a minimal TATA box was used. A phRL-thymidine kinase (TK) vector containing sea pansy 
(Renilla reniformis) luciferase gene under control of the herpes simplex virus-TK promoter was the third 
vector co-transfected. The latter two plasmids were procured from promega.  
Dual-Glo luciferase gene reporter assay 
pRC-APP695-Gal4 and pFR-Luciferase (0.5 µg) were transfected into primary cortical neurons cultured 
in 24-well plates  at 5 DIV, using Lipofectamine 2000 (1 µL/well). All wells were co-transfected with 
phRL-TK-Renilla (0.5 µg) as an internal control for luciferase expression. Transfection mixes containing 
lipid and DNA were prepared separately in OptiMEM I reduced serum medium (Gibco, #31985062), then 
mixed and incubated at RT for 25 min. After incubation, 75 µL/well transfection mix was added drop 
wise to the cells and incubated for 2 h. In one set of experiment, primary cortical neurons were pre-treated 
with γ-secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-Lalanyl]-(S)-phenylglycine t-butyl ester  for 30 
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min followed by transfection and treatment with HSA or AGE-HSA for 24 h (Figure 5A). In second set of 
experiment, primary cortical neurons were pre-treated with Cathepsin B inhibitor, CA074-Me or anti-
RAGE antibody, H300 for 30 min followed by transfection and treatment with HSA or AGE-HSA for 8 
h. Post treatment, quantification of firefly luciferase and renilla luciferase expression was measured 
(Figure 5B). Neurons were lysed with Glo-lysis buffer (50 µL/well) (Promega, #E2661), and the Dual-
Glo luciferase activity assay was performed according to the manufacturer’s instructions (Promega, 
#E2940). Luciferase signals were captured using a microplate luminometer (Promega). Firefly luciferase 
reporters activity was normalized using the renilla luciferase activity, which helps to differentiate between 
specific and nonspecific cellular responses and control for transfection efficiencies across experiments.35 
Determination of Aβ1-42 release 
To determine the effect of AGE-HSA on Aβ1-42 release from primary cortical neurons, cells were grown 
in 6 well plates, the conditioned neuronal growth medium at 5 DIV was removed, and neurons were 
washed twice with warm (37°C) PBS, pH 7.4, to remove Aβ that had accumulated with time in culture. 
Then, 500 µl of fresh, warm (37°C) neurobasal medium without phenol red, supplemented with B-27, 
containing either HSA or glycated HSA; in the presence or absence of Cathepsin B inhibitor (CA074Me) 
or BACE 1 inhibitor (AZD3293) or Anti-RAGE antibody (H300) was added to the neurons for a further 
24 h. The neurobasal medium (300 µl) was harvested and transferred to 1.5 ml tubes containing complete 
protease inhibitor cocktail and centrifuged at 10,000 × g for 30 min at 4°C. Samples (200 µl) were then 
added to a mouse Aβ1-42 ELISA plate and processed for detection of Aβ1-42 according to the 
manufacturer's instructions (Invitrogen, #KMB3441). Aβ1-42 levels in conditioned medium were 
calculated from a mouse Aβ1-42 standard curve. 
Human tissue samples 
Human brain tissue homogenates were provided by the London Neurodegenerative Brain Bank which is 
funded by grants from the UK Medical Research Council and by Brains for Dementia Research, a joint 
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venture between Alzheimer’s Society and Alzheimer’s Research UK.Brains for Dementia Research has 
ethics approval from London–City and East NRES committee 08/H0704/128+5 and all participants gave 
informed consent for their tissue to be used in research. Tissue samples from the temporal cortex were 
dissected from frozen brains of 3 AD cases (age 84.3 ± 6.3 years) and 3 age matched controls (age 89.3 ± 
11.3 years) and were homogenised in RIPA buffer at King’s College London, UK. 
Statistical analyses  
Statistical analyses were performed using either Student’s t-test (two-group comparison) or one-way 
ANOVA. Unpaired t-test was used to study the differential expression of proteins in human brain tissue 
homogenates of Normal and AD subjects. 
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ABBREVIATIONS   
AD Alzheimer’s disease  
AEP Asparagine Endopeptidase 
AGE Advanced glycation end products 
Aβ Amyloid beta  
APP Amyloid precursor protein 
BACE1 Beta-secretase 1 
CML Carboxymethyllysine  
CTF C-terminal fragments 
β-CTF C-terminal fragment of β-secretase cleavage 
DIV Days in vitro 
DCF-DA 2′,7′-Dichlorofluorescin diacetate 
GSK3β Glycogen synthase kinase 3β 
HSA Human serum albumin 
PP2A Protein phosphatase 2A 
RAGE Receptor for advanced glycation end productsSWATH Sequential window acquisition of all 
theoretical fragment ion spectra 
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FIGURE LEGENDS  
Figure 1: Effect of AGEs on the viability of neuro2a cells in vitro. Neuro2a cells were treated with 
different concentrations of HSA or AGE-HSA (0.1, 0.5, 1.0 and 1.5 mg/ml) for 24 h. The effect of AGEs 
on the viability of cells was analyzed by MTT assay. One-way ANOVA was used to calculate the 
variances in HSA and AGE-HSA treated groups.  
Figure 2: Measurement of AGE-HSA induced ROS production and apoptosis in neuro2a cells. (A) 
ROS generation after HSA or AGE-HSA stimulation was measured in neuronal cells using H2DCF-DA 
after administration of 1 h. H2DCF-DA only treated cells served as control and fold change is presented 
relative to control measured by spectrofluorometer. (B) Neuro2a cells were treated with control, HSA, or 
AGE-HSA for 1 h, and DCF-DA fluorescence images were obtained at 30 min after treatment (Upper 
panel depicts the bright field images while lower panel shows the green field images). Flow cytometric 
analysis of neuro2a cells treated with (C) HSA or (D) AGE-HSA using Annexin V-FITC Apoptosis 
Detection Kit. (E) Bar graph depicting the percentage of apoptotic cells upon HSA or AGE-HSA 
stimulation. FITC, fluorescein isothiocyanate; PI, propidium iodide; BF, bright field; GF, green field. 
Student’s t-test was used to compare ROS generation after HSA and AGE treatments.  
Figure 3: AGE-HSA regulates the expression of several proteins associated with different metabolic 
function in neuronal cells. Pathway analysis of (A) up regulated and (B) down regulated proteins upon 
AGE-HSA stimulation by DAVID. Potential transcription factors co-regulating (C) up regulated and (D) 
down regulated proteins predicted using cytoscapeplugin, iRegulon. (E)  Protein-protein interactions 
between deregulated proteins were analysed by using String and closely interacting proteins were 
identified using MCL algorithm of Clustermaker2 plugin in Cytoscape. (F) Bar graph demonstrating the 
fold change in the expression of key proteins implicated in AD. (Pathways represented in bar graph are 
with P<0.05) 
Figure 4: Western blot analysis of Cathepsin B and AEP in neuro2a cells and primary cortical 
neurons. The levels of Cathepsin B and AEP expressed were measured in neuro2a cells (shown in A, B 
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and C) and in primary cortical neurons (shown in D, E and F) after HSA or AGE stimulation. A beta-
tubulin was used to normalize the possible loading errors. (A) Western blot analysis of Cathepsin B and 
AEP expressed in the neuro2a cells after AGE stimulation for 24 hours. (B) Quantitative analysis of 
Cathepsin B levels detected with Western blot in neuro2a cells. The level of Cathepsin B protein 
expressed in control was set as 100%; levels of Cathepsin B expressed after 24 hours of HSA or AGE 
stimulation were calculated by comparing to that of control. Densitometric analysis showed a significant 
increase in Cathepsin B levels after AGE stimulation. (C) Quantitative analysis of AEP levels detected 
with Western blot in neuro2a cells. The level of AEP protein expressed in control was set as 100%; levels 
of AEP expressed after HSA or AGE stimulation were calculated by comparing to that of control. 
Densitometric analysis showed a significant increase in AEP levels after AGE stimulation. (D) Western 
blot analysis of Cathepsin B and AEP expressed in the primary cortical neurons after AGE stimulation for 
24 hours. (E) Quantitative analysis of Cathepsin B levels detected with Western blot in primary cortical 
neurons. The level of Cathepsin B protein expressed in control was set as 100%; levels of Cathepsin B 
expressed after 24 hours of HSA or AGE or H300/AGE stimulation were calculated by comparing to that 
of control. Densitometric analysis showed a significant increase in Cathepsin B levels after AGE 
stimulation and blocking RAGE with an anti-RAGE antibody (H300) abolished AGE-induced Cathepsin 
B expression. (F) Quantitative analysis of AEP levels detected with Western blot in primary cortical 
neurons. The level of AEP protein expressed in control was set as 100%; levels of AEP expressed after 
HSA or AGE or H300/AGE stimulation were calculated by comparing to that of control. Densitometric 
analysis showed a significant increase in AEP levels after AGE stimulation and blocking RAGE with an 
anti-RAGE antibody (H300) abolished AGE-induced AEP expression. One-way ANOVA was used to 
compare the expression of Cathepsin B and AEP across treatments in neuro2a cells and primary cortical 
neurons. 
Figure 5: AGE stimulation increases Cathepsin B-dependent amyloidogenic APP processing in 
primary cortical neurons through RAGE. (A) Primary cortical neurons were transfected with plasmid 
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encoding pFR-Luc firefly luciferase reporter gene and APP695-Gal4. All cells were co-transfected with 
phRL-TK plasmid that constitutively expresses Renilla luciferase. Dual-Glo luciferase activity assays 
were performed 24 h after HSA or AGE-HSA treatment for quantification of firefly and Renilla luciferase 
expression. Firefly luciferase activity was normalized using the Renilla luciferase activity. Cells were 
treated with 10 µM N-[N-(3,5-Diflurophenaacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester for 30 min 
before transfection. The assay result shows the increased expression of pFR-Luc firefly luciferase upon 
AGE stimulation. (B) Primary cortical neurons were treated with 5 µM CA074-Me or4 µg/ml H300 for 30 
min before co-transfection with pFR-Luc firefly luciferase reporter gene, APP695-Gal4 and phRL-TK 
plasmids. Dual-Glo luciferase activity assay was performed 8 h after HSA or AGE-HSA stimulation for 
quantification of firefly and Renilla luciferase expression. Firefly luciferase activity was normalized using 
the Renilla luciferase activity. The assay result shows that pre-treatment of CA074-Me orH300 blocked 
the AGE induced expression of pFR-Luc firefly luciferase.(C) Western blot show the effect of HSA, 
AGE-HSA, CA074Me, H300 or AZD3293 (BACE1 inhibitor) on APP-CTFs formation. (D) ELISA result 
show the elevated release of Aβ1-42 from primary cortical neurons after AGE-HSA stimulation which was 
decreased with pre-treatment of CA074-Me, H300 and AZD3293.*P<0.05, **P<0.005, ***P<0.0005, 
****P<0.00005. One-way ANOVA was used to compare the Aβ1-42 formation across control and 
treatment groups.  
Figure 6: Western blot analysis of phosphorylated and total tau in primary cultured cortical 
neurons. The levels of tau and pTau were measured in primary cortical neurons (shown in A, B and C) 
after HSA or AGE-HSA or H300/AGE stimulation. A beta-tubulin was used to normalize the possible 
loading errors. (A) Western blot analysis of Tau and pTau after HSA or AGE or H300/AGE stimulation 
for 24 hours. (B) Quantitative analysis of Tau levels detected with Western blot in primary cortical 
neurons. The level of Tau protein expressed in control was set as 100%; levels of Tau expressed after 24 
hours of HSA or AGE or H300/AGE stimulation were calculated by comparing to that of control. 
Densitometric analysis showed a no change in the expression of Tau levels after AGE stimulation. (C) 
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Quantitative analysis of pTau levels detected with Western blot in primary cortical neurons. The level of 
pTau protein in control was set as 100%; levels of pTau expressed after 24 hours of HSA or AGE or 
H300/AGE stimulation were calculated by comparing to that of control. Densitometric analysis showed a 
notable increase in pTau levels after AGE stimulation. One-way ANOVA was used to study the levels of 
Tau and pTau in control and treatment groups. 
Figure 7: Representative western blot analysis of brain tissue lysates from the temporal cortex of 
AD subjects compared with age matched controls. (A) The levels of glycated proteins (CML 
modified), RAGE, Cathepsin B, AEP and pTau were measured in normal and AD subjects. Raw intensity 
values (without normalization) are plotted for the quantitative analysis of western blots. (B) Quantitative 
analysis of carboxymethylated protein levels detected with Western blot in Healthy and AD subjects. 
Densitometric analysis showed a notable increase in glycated protein levels in AD subjects. (C) 
Quantitative analysis of RAGE expression detected by Western blot in Healthy and AD subjects. 
Densitometric analysis showed elevated RAGE expression in AD subjects as compared to Normal. (D) 
Quantitative analysis of Cathepsin B protein levels detected by Western blot in Healthy and AD subjects. 
Densitometric analysis showed increased levels of Cathepsin B in AD subjects. (E) Quantitative analysis 
of AEP protein levels detected by Western blot in Healthy and AD subjects. Densitometric analysis 
showed elevated levels of AEP in AD subjects than healthy individuals. (F) Quantitative analysis of pTau 
levels detected by Western blot in Healthy and AD subjects. Densitometric analysis showed elevated 
levels of pTau in AD subjects than normal individuals. The unpaired t-test was used to study the 
differential expression of proteins in human brain tissue homogenates. 
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TABLES AND FIGURES 
Table 1: Levels of RAGE, Cathepsin B, AEP, pTau and CML modified proteins in Normal and AD 
subjects normalized with beta-tubulin.                            
Data is expressed as Mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. No. 
Protein 
Name 
Ratio to β-tubulin 
p Value 
Normal AD 
1 CML 0.72±0.39 11.75±3.99 0.0513  
2 RAGE 0.35±0.22 4.73±1.3  0.0299 
3 Cathepsin B 0.17±0.10 3.09±0.95 0.0388 
4 AEP 0.18±0.08 3.35±1.22 0.0615 
5 pTau 0.12±0.06 3.16±0.75 0.016 
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